𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease

✍ Scribed by R. Inzelberg; P. Nisipeanu; M. J. Rabey; Prof. A. D. Korczyn

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
333 KB
Volume
10
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a long half‐life and can be given in a single daily dose. Seventeen patients with severe fluctuations were treated with cabergoline, seven of them for >1 year (up to 39 months). The motor status ameliorated and the percentage of “off” hours significantly decreased in the first year and did not increase significantly later during long‐term follow‐up. Cabergoline is a promising treatment for parkinsonian patients with motor fluctuations.

📜 SIMILAR VOLUMES

Long-term antidyskinetic efficacy of ama
Long-term antidyskinetic efficacy of amantadine in Parkinson's disease
✍ Elisabeth Wolf; Klaus Seppi; Regina Katzenschlager; Guenter Hochschorner; Gerhar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 1 views

## Abstract Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodop

Long-term efficacy and safety of pramipe
Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial
✍ J. Carsten Möller; Wolfgang H. Oertel; Jürgen Köster; Gianni Pezzoli; Leandro Pr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

## Abstract A double‐blind, placebo‐controlled study with a subsequent open‐label phase was conducted in 354 patients with Parkinson's disease (PD) and motor fluctuations under individually adjusted therapy with levodopa. During the double‐blind phase 174 patients received pramipexole and 180 place

Efficacy of long-term continuous subcuta
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
✍ Pedro J. García Ruiz; Ángel Sesar Ignacio; Begoña Ares Pensado; Alfonso Castro G 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## Abstract Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations. We studied the evolution of patients with PD and severe motor fluctuations long‐term treated with CSAI. We reviewed data from 82 patie

Long-term results of a multicenter study
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease
✍ Elena Moro; Andres M. Lozano; Pierre Pollak; Yves Agid; Stig Rehncrona; Jens Vol 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

## Abstract We report the 5 to 6 year follow‐up of a multicenter study of bilateral subthalamic nucleus (STN) and globus pallidus internus (GPi) deep brain stimulation (DBS) in advanced Parkinson's disease (PD) patients. Thirty‐five STN patients and 16 GPi patients were assessed at 5 to 6 years aft

Double-blind study of pardoprunox, a new
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
✍ Juliana Bronzova; Cristina Sampaio; Robert A. Hauser; Anthony E. Lang; Olivier R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

## Abstract This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's o